Oxford Biomedica new manufacturing suite approved
Oxford Biomedica
412.50p
16:39 19/11/24
0.61%
2.50p
Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
FTSE 250
20,427.62
16:34 19/11/24
n/a
n/a
FTSE 350
4,469.52
16:34 19/11/24
n/a
n/a
FTSE All-Share
4,427.06
16:59 19/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,328.21
16:34 19/11/24
0.64%
123.81
Approval was given by the UK Medicines & Healthcare products Regulatory Agency, the company said on Tuesday.
“Both this suite and the suite approved in September …at present will be dedicated to the manufacture of a Covid-19 viral vector vaccine candidate,” Oxford said.
“This world class facility is suitable for the manufacture of a variety of viral vectors and the approval of this fourth suite completes a phase of expansion that more than doubles Oxford Biomedica's manufacturing capacity compared to 2019, supporting further growth in revenues and partner programmes.”